Sensei Biotherapeutics

SNSE

Market cap $10.6M

Overview Fund Activity

8.41 USD

-0.61

6.76%

At close Updated Sep 16, 9:56 AM EDT

1 day

-6.76%

5 days

-3.33%

1 month

1.69%

3 months

28.99%

6 months

-4.86%

Year to date

-18.35%

1 year

-12.21%

5 years

-97.78%

10 years

-97.78%

About: Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Employees: 15

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.11% less ownership

Funds ownership: 0.38% [Q1] → 0.28% (-0.11%) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

21% less capital invested

Capital invested by funds: $760K [Q1] → $600K (-$160K) [Q2]

50% less funds holding

Funds holding: 20 [Q1] → 10 (-10) [Q2]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$30

257% upside

Avg. target

$30

257% upside

High target

$30

257% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Joseph Pantginis

$30

Buy

Maintained

5 Aug 2025

See Analyst Rankings

Financial journalist opinion

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C.

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

The Motley Fool

Sensei (SNSE) Q2 Loss Narrows 31%

Sensei (SNSE) Q2 Loss Narrows 31%

Sensei (SNSE) Q2 Loss Narrows 31%

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. “The second quarter was a key inflection point for Sensei, as we now transition from early response-focused readouts to longer-term and commercially relevant efficacy signals with the maturity of the data from our Phase 1/2 study of solnerstotug,” said John Celebi, President and CEO of Sensei.

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

These 3 health tech stocks spiked 37% in a day; Time to buy?

While the broader stock market suffered steep losses on Friday amid trade policy shifts and troubling economic data, select health technology equities stood out.

These 3 health tech stocks spiked 37% in a day; Time to buy?

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron's PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany.

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “This was a breakthrough quarter for Sensei,” said John Celebi, President and CEO.

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET.

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population -

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing –

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

See News Rankings

Charts implemented using Lightweight Charts™